RadNet (RDNT) announced that it has completed the acquisition of iCAD (ICAD). The integration of iCAD’s complementary commercial, technology, and regulatory capabilities into DeepHealth advances DeepHealth’s mission to address clinical and operational challenges in screening and diagnosis by harnessing the power of AI and imaging. Kees Wesdorp, President and CEO of RadNet’s Digital Health segment, commented, “We are excited to welcome the iCAD team to DeepHealth. The integration of iCAD further empowers DeepHealth to meet the real-world clinical needs of today, from improving the accuracy and early detection of breast cancer to orchestrating large-scale screening programs, while shaping the future of breast cancer management. Our combined capabilities position us for accelerated growth and rapid delivery of transformative, AI-powered population health solutions.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RDNT:
- RadNet to be reimbursed for its EBCD program
- iCAD’s proposed acquisition by RadNet recommended by ISS, Glass Lewis
- RadNet initiated with a Buy at B. Riley
- RadNet Secures $100 Million Loan for Growth
- RadNet’s Strategic Acquisition of See-Mode Technologies: A Boost to AI Capabilities and Revenue Growth